HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chiasson, J.-L. Articles by Naditch, L. Search for Related Content PubMed PubMed Citation Articles by Chiasson, J.-L. Articles by Naditch, L. Social Bookmarking                What's this?

The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes

¹ Research Group on Diabetes and Metabolic Regulation, Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
² Sanofi-Synthelabo, Paris, France

OBJECTIVE—To investigate the efficacy and safety of miglitol in combination with metformin in improving glycemic control in outpatients in whom type 2 diabetes is insufficiently controlled by diet alone.

RESEARCH DESIGN AND METHODS—In this multicenter, double-blind, placebo-controlled study, 324 patients with type 2 diabetes were randomized, after an 8-week placebo run-in period, to treatment with either placebo, miglitol alone, metformin alone, or miglitol plus metformin for 36 weeks. The miglitol was titrated to 100 mg three times a day and metformin was administered at 500 mg three times a day. The primary efficacy criterion was change in HbA_1c from baseline to the end of treatment. Secondary parameters included changes in fasting and postprandial plasma glucose and insulin levels, serum triglyceride levels, and responder rate.

RESULTS—A total of 318 patients were valid for intent-to-treat analysis. A reduction in mean placebo-subtracted HbA_1c of -1.78% was observed with miglitol plus metformin combination therapy, which was significantly different from treatment with metformin alone (-1.25; P = 0.002). Miglitol plus metformin also resulted in better metabolic control than metformin alone for fasting plasma glucose (-44.8 vs. -20.4 mg/dl; P = 0.0025), 2-h postprandial glucose area under the curve (-59.0 vs. –18.0 mg/dl; P = 0.0001), and responder rate (70.6 vs. 45.52%; P = 0.0014). All therapies were well tolerated.

CONCLUSIONS—In type 2 diabetic patients, miglitol in combination with metformin gives greater glycemic improvement than metformin monotherapy.

Abbreviations: AUC, area under the curve • ITT, intent to treat

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]

				F. A. van de Laar, P. L. Lucassen, R. P. Akkermans, E. H. van de Lisdonk, G. E. Rutten, and C. van Weel {alpha}-Glucosidase Inhibitors for Patients With Type 2 Diabetes: Results from a Cochrane systematic review and meta-analysis Diabetes Care, January 1, 2005; 28(1): 154 - 163. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				A. J. Scheen and P. J. Lefebvre Potential Pharmacokinetics Interference Between {alpha}-Glucosidase Inhibitors and Other Oral Antidiabetic Agents Diabetes Care, January 1, 2002; 25(1): 247 - 248. [Full Text] [PDF]